糖尿病患者合并细菌性肺炎的研究进展

doi:10.20223/j.cnki.1000-8535.2025.09.004

摘要/Abstract

摘要： 随着糖尿病患者的增加,因肺炎住院的糖尿病患者数也呈现出明显上升趋势。由于糖代谢紊乱及机体免疫功能下降等因素,细菌在高血糖的机体环境中快速繁殖并分泌大量毒素,增加了抗菌药物使用的时间跨度和细菌清除难度,对患者预后造成了极大的威胁。文章主要对糖尿病合并细菌性肺炎患者的病原学特征、耐药情况及药物治疗等进行阐述,旨在进一步为临床预防和治疗提供参考依据。

关键词: 糖尿病, 高血糖, 肺炎, 病原菌

Abstract: With the increasing incidence in diabetes,the number of hospitalized diabetes patients with pneumonia is also increasing. Due to factors such as glucose metabolism disorders and decreased immune function in the body,bacteria rapidly multiply and secrete a large amount of toxins in the hyperglycemic environment,increasing the duration of antibiotic use and the difficulty of bacterial clearance,posing a great threat to patient prognosis. This article mainly elaborates on the pathogenic characteristics,drug resistance,and drug treatment of diabetes patients with bacterial pneumonia,aiming to provide reference for the clinical prevention and treatment.

Key words: diabetes, hyperglycemia, pneumonia, pathogens

邓冬燕, 秦振昆, 高静, 张营, 刘延雯. 糖尿病患者合并细菌性肺炎的研究进展[J]. 广州医药, 2025, 56(9): 1182-1188.

DENG Dongyan, QIN Zhenkun, GAO Jing, ZHANG Ying, LIU Yanwen. Research progress on diabetes mellitus patients with bacterial pneumonia[J]. Guangzhou Medical Journal, 2025, 56(9): 1182-1188.

参考文献

[1] HARDING J L,BENOIT S R,GREGG E W,et al.Trends in rates of infections requiring hospitalization among adults with versus without diabetes in the U. S.,2000-2015[J].Diabetes Care,2020,43(1):106-116.
[2] HUANG D,HE D,GONG L,et al.Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia and type 2 diabetes mellitus[J].Crit Care,2021,25(1):419.
[3] WU H,LAU E S H,MA R C W,et al.Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong,2001-2016:A retrospective cohort study[J].Diabetologia,2020,63(4):757-766.
[4] YI H,HUANG J,GUO L,et al.Increased antimicrobial resistance among sputum pathogens from patients with hyperglycemia[J].Infect Drug Resist,2020(13):1723-1733.
[5] 张丽,赵静,王晨菲.2型糖尿病合并肺部感染病原菌类型及肺部CT特征分析[J].中国病原生物学杂志,2023,18(5):589-592,597.
[6] 包萨日娜,李武武.2型糖尿病肺部感染病原学特点及危险因素分析[J].中国城乡企业卫生,2023,38(8):15-18.
[7] ZHANG Q R,CHEN H,LIU B,et al.Methicillin-resistant Staphylococcus aureus pneumonia in diabetics:A single-center,retrospective analysis[J].Chin Med J,2019,132(12):1429-1434.
[8] DONG W,FAN X,GUO Y,et al.An expanded database and analytical toolkit for identifying bacterial virulence factors and their associations with chronic diseases[J].Nat Commun,2024,15(1):8084.
[9] SONG S,YANG S,ZHENG R,et al.Adaptive evolution of carbapenem-resistant hypervirulent Klebsiella pneumoniae in the urinary tract of a single patient[J].Proc Natl Acad Sci U S A,2024,121(35):e2400446121.
[10] TANG L,WANG H,CAO K,et al.Epidemiological features and impact of high glucose level on virulence gene expression and serum resistance of klebsiella pneumoniae causing liver abscess in diabetic patients[J].Infect Drug Resist,2023(16):1221-1230.
[11] HUANG Y C,KUO S C,FANG C T,et al.Changing epidemiology and antimicrobial resistance of bacteria causing bacteremia in Taiwan:2002-2020[J].Microbiol Spectr,2024,12(8):e0060824.
[12] PATTOLATH A,ADHIKARI P,PAI V.Carbapenemase-producing klebsiella pneumoniae infections in diabetic and nondiabetic hospitalized patients[J].Cureus,2024,16(1):e52468.
[13] FAN Z,FU T,LIU H,et al.Glucose induces resistance to polymyxins in high-alcohol-producing klebsiella pneumoniae via increasing capsular polysaccharide and maintaining intracellular ATP[J].Microbiol Spectr,2023,11(4):e0003123.
[14] LIU B,YI H,FANG J,et al.Antimicrobial resistance and risk factors for mortality of pneumonia caused by Klebsiella pneumoniae among diabetics:A retrospective study conducted in Shanghai,China[J].Infect Drug Resist,2019(12):1089-1098.
[15] CHEN J,XIA B,LIU Y,et al.Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae:A retrospective cohort study[J].Ann Med,2024,56(1):2397087.
[16] CUI Z,WANG L,FENG M.Clinical and epidemiological characteristics of carbapenem-resistant klebsiella pneumoniae infections in a tertiary hospital in China[J].Microb Drug Resist,2023,29(9):401-406.
[17] FU Q,LIU S,HU P,et al.Diclofenac sodium restores the sensitivity of colistin-resistant gram-negative bacteria to colistin[J].ACS Infect Dis,2024,10(8):2860-2869.
[18] TÜZEMEN N Ü,ÖNAL U,MERDAN O,et al.Synergistic antibacterial activity of ceftazidime-avibactam in combination with colistin,gentamicin,amikacin,and fosfomycin against carbapenem-resistant Klebsiella pneumoniae[J].Sci Rep,2024,14(1):17567.
[19] GEDEFIE A,DEMSIS W,ASHAGRIE M,et al.Acinetobacter baumannii biofilm formation and its role in disease pathogenesis:A review[J].Infect Drug Resist,2021(14):3711-3719.
[20] BORAL B,UNALDI Ö,ERGIN A,et al.A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features[J].Ann Clin Microbiol Antimicrob,2019,18(1):19.
[21] HAYAKAWA K,BINH N G,CO D X,et al.Clinical and microbiological evaluation of ventilator-associated pneumonia in an intensive care unit in Vietnam[J].Infect Prev Pract,2023,5(4):100318.
[22] TAMMA P D,AITKEN S L,BONOMO R A,et al.Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections[J].Clin Infect Dis,2023:ciad428.
[23] SEOK H,CHOI W S,LEE S,et al.What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii(CRAB):A multicentre study in Korea[J].J Glob Antimicrob Resist,2021(24):429-439.
[24] NIU T,LUO Q,LI Y,et al.Comparison of tigecycline or cefoperazone/sulbactam therapy for bloodstream infection due to carbapenem-resistant acinetobacter baumannii[J].Antimicrob Resist Infect Control,2019(8):52.
[25] KAYE K S,SHORR A F,WUNDERINK R G,et al.Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex:A multicentre,randomised,active-controlled,phase 3,non-inferiority clinical trial(ATTACK)[J].Lancet Infect Dis,2023,23(9):1072-1084.
[26] ZHAN Y,MAO W,ZHAO C,et al.Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii:A systematic review with meta-analysis and trial sequential analysis[J].BMC Infect Dis,2024,24(1):967.
[27] RAO S,BETANCOURT-GARCIA M,KARE-OPANEYE Y O,et al.Critically Ill patient with multidrug-resistant acinetobacter baumannii respiratory infection successfully treated with intravenous and nebulized bacteriophage therapy[J].Antimicrob Agents Chemother,2022,66(1):e0082421.
[28] CASTELLANOS N,NAKANOUCHI J,YÜZEN D I,et al.A study on acinetobacter baumannii and staphylococcus aureus strains recovered from the same infection site of a diabetic patient[J].Curr Microbiol,2019,76(7):842-847.
[29] KRISHNAN M,CHOI J,JANG A,et al.Antiseptic 9-Meric peptide with potency against carbapenem-resistant acinetobacter baumannii infection[J].Int J Mol Sci,2021,22(22):12520.
[30] LEUNG C H,LIU C P.Diabetic status and the relationship of blood glucose to mortality in adults with carbapenem-resistant Acinetobacter baumannii complex bacteremia[J].J Microbiol Immunol Infect,2019,52(4):654-662.
[31] SURESH S,NAIK A,PREMANATH R.Glucose-induced enhanced virulence in strains of multidrug-resistant pseudomonas aeruginosa isolated from diabetic patients[J].Curr Microbiol,2023,80(3):100.
[32] YU S,XU C,TANG X,et al.Exendin-4 blockade of T1R2/T1R3 activation improves Pseudomonas aeruginosa-related pneumonia in an animal model of chemically induced diabetes[J].Inflamm Res,2024,73(7):1185-1201.
[33] SHE P,WANG Y,LIU Y,et al.Effects of exogenous glucose on Pseudomonas aeruginosa biofilm formation and antibiotic resistance[J].Microbiologyopen,2019,8(12):e933.
[34] CHEN T,XU Y,XU W,et al.Hypertonic glucose inhibits growth and attenuates virulence factors of multidrug-resistant Pseudomonas aeruginosa[J].BMC Microbiol,2020,20(1):203.
[35] 王艳,曹洪兵,丁妍.2 437株临床病原菌分布及其耐药性分析[J].中国病原生物学杂志,2024,19(2):209-212.
[36] TRUONG C N,CHIN-BECKFORD N,VEGA A,et al.Duration of antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia:Is shorter truly better[J].BMC Infect Dis,2024,24(1):911.
[37] MIAO Z Y,ZHANG X Y,LONG H Z,et al.Hybrids of 3-hydroxypyridin-4(1H)-ones and long-chain 4-aminoquinolines as potent biofilm inhibitors of pseudomonas aeruginosa potentiate tobramycin and polymyxin B activity[J].J Med Chem,2024,67(18):16835-16857.
[38] ZAIDAN I,CARVALHO A F S,GROSSI L C,et al.The angiotensin-(1-7)/MasR axis improves pneumonia caused by Pseudomonas aeruginosa:Extending the therapeutic window for antibiotic therapy[J].FASEB J,2024,38(18):e70051.
[39] MOULE M G,BENJAMIN A B,BURGER M L,et al.Peptide-mimetic treatment of Pseudomonas aeruginosa in a mouse model of respiratory infection[J].Commun Biol,2024,7(1):1033.
[40] GACH M W,LAZARUS G,SIMADIBRATA D M,et al.Antimicrobial resistance among common bacterial pathogens in Indonesia:A systematic review[J].Lancet Reg Health Southeast Asia,2024(26):100414.
[41] GENITO C J,DARWITZ B P,GREENWALD M A,et al.Hyperglycemia potentiates increased Staphylococcus aureus virulence and resistance to growth inhibition by Pseudomonas aeruginosa[J].Microbiol Spectr,2023,11(6):e0229923.
[42] JING Q,LIU R,JIANG Q,et al.Staphylococcus aureus wraps around Candida albicans and synergistically escapes from Neutrophil extracellular traps[J].Front Immunol,2024(15):1422440.
[43] MOYA-SALAZAR J,CHAMANA J M,PORRAS-RIVERA D,et al.Increase in antibiotic resistance in diabetic foot infections among peruvian patients:A single-center cross-sectional study[J].Front Endocrinol(Lausanne),2023(14):1267699.
[44] LIU W,SONG L,SUN W,et al.Distribution of microbes and antimicrobial susceptibility in patients with diabetic foot infections in South China[J].Front Endocrinol(Lausanne),2023(14):1113622.
[45] 范亚新. 万古霉素治疗严重耐甲氧西林金黄色葡萄球菌感染的治疗药物监测:2020年美国卫生系统药师协会、美国感染病学会、儿童感染性疾病学会和感染病药师学会更新修订的共识指南[J].中国感染与化疗杂志,2021,21(3):374-376.
[46] KOZIEń Ł,POLICHT A,HECZKO P,et al.PDIA iminosugar influence on subcutaneous Staphylococcus aureus and Pseudomonas aeruginosa infections in mice[J].Front Cell Infect Microbiol,2024(14):1395577.
[47] FUKUDA H,ONIZUKA H,NISHIMURA N,et al.Risk factors for pneumococcal disease in persons with chronic medical conditions:Results from the LIFE Study[J].Int J Infect Dis,2022(116):216-222.
[48] SUNDARAMURTHY S S R,ALLEN K E,FLETCHER M A,et al.Retrospective database analysis for clinical diagnoses commonly associated with pneumococcal diseases in the Malaysian healthcare system over a 3-year period(2013-2015)[J].BMC Infect Dis,2024,24(1):79.
[49] MIAO C,YAN Z,CHEN C,et al.Serotype,antibiotic susceptibility and whole-genome characterization of Streptococcus pneumoniae in all age groups living in Southwest China during2018-2022[J].Front Microbiol,2024(15):1342839.
[50] 李艳明,陈丽华,付陈超,等.湖南省细菌耐药监测网2012—2021年呼吸道分离菌耐药性监测[J].中国感染控制杂志,2024,23(4):429-441.
[51] MOHANTY S,JOHNSON K D,YU K C,et al.A multicenter evaluation of trends in antimicrobial resistance among Streptococcus pneumoniae isolates from adults in the United States[J].Open Forum Infect Dis,2022,9(9):ofac420.
[52] MARAKI S,MAVROMANOLAKI V E,STAFYLAKI D,et al.Antimicrobial resistance of Streptococcus pneumoniae clinical serotypes between 2017 and 2022 in Crete,Greece[J].Infect Chemother,2024,56(1):73-82.
[53] KIM G R,KIM E Y,KIM S H,et al.Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae causing invasive pneumococcal disease in Korea between 2017 and 2019 after introduction of the 13-valent pneumococcal conjugate vaccine[J].Ann Lab Med,2023,43(1):45-54.
[54] LAO M,LI C,LI J,et al.Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China:Clinical features and associated factors[J].J Diabetes Investig,2020,11(3):731-744.
[55] JIMÉNEZ-ESCUTIA R,VARGAS-ALCANTAR D,FLORES-ESPINOSA P,et al.High glucose promotes inflammation and weakens placental defenses against E.coli and S.agalactiae infection:Protective role of insulin and metformin[J].Int J Mol Sci,2023,24(6):5243.
[56] CHEN H H,CHEN C C,HO C W,et al.Dipeptidyl peptidase-4 inhibitor treatment could decrease Klebsiella pneumoniae pneumonia in patients with type 2 diabetes[J].Postgrad Med,2020,132(8):714-719.
[57] LIU L,FAN H,LI L,et al.Acarbose reduces Pseudomonas aeruginosa respiratory tract infection in type 2 diabetic mice[J].Respir Res,2023,24(1):312.
[58] GU S,FAN B,WAN F,et al.Antibacterial activity and mechanism of canagliflozin against methicillin-resistant staphylococcus aureus[J].Molecules,2023,28(15):5668.
[59] LEE J Y,KIM E S,CHANG E,et al.Clinical impact of metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus[J].Eur J Clin Microbiol Infect Dis,2023,42(12):1439-1447.
[60] NI L,LI Y,ZHANG H,et al.The combination of insulin and linezolid ameliorates Staphylococcus aureus pneumonia in individuals with diabetes via the TLR2/MAPKs/NLRP3 pathway[J].Int J Biol Macromol,2023,242(Pt 1):124750.